Ticagrelor represents a safe treatment option after fibrinolysis for ST-elevation myocardial infarction (STEMI), with 12-month results from the TREAT study showing it was noninferior to clopidogrel. The primary endpoint (major bleeding at 30 days) was previously reported in 2018 showing comparable safety between ticagrelor and clopidogrel. Now the results for 12 months have been released ...
Ticagrelor safe after fibrinolysis – and now there’s a reversal agent
By Michael Woodhead
22 Mar 2019